Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Magnesium aspartate dihydrate (Magnaspartate®) is recommended as an option for use within NHS Wales for the treatment and prevention of magnesium deficiency, as diagnosed by a doctor, in adults, children and adolescents aged from two years. |
|||
|
|||
Medicine details |
|||
| Medicine name | magnesium aspartate dihydrate (Magnaspartate®) | ||
| Formulation | 243 mg powder for oral solution | ||
| Reference number | 2596 | ||
| Indication | Treatment and prevention of magnesium deficiency, as diagnosed by a doctor, in adults, children and adolescents aged from 2 years |
||
| Company | Kora Corporation Ltd trading as Kora Healthcare | ||
| BNF chapter | Nutrition & blood | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 2215 | ||
| NMG meeting date | 10/06/2015 | ||
| AWMSG meeting date | 15/07/2015 | ||
| Ratification by Welsh Government | 27/08/2015 | ||
| Date of issue | 02/09/2015 | ||
| Date of last review | 26/03/2019 | ||